Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a sale of
Twist Bioscience insider filings show a proposed sale under Rule 144 and multiple recent disposals of common stock. The notice reports an intended sale of 140 shares through Fidelity Brokerage Services with an approximate sale date of 10/02/2025 and an aggregate market value of $4,082.53. The shares were acquired on 10/01/2025 by restricted stock vesting and were paid as compensation. The filer also disclosed five prior sales by Paula Green between 07/02/2025 and 09/22/2025, totaling 3,203 shares and gross proceeds of $86,716.21. The filing records 60,360,925 shares outstanding for the issuer and includes the required attestation that no undisclosed material adverse information is known to the seller.
Form 144 notice for Twist Bioscience Corp (TWST) shows an officer or insider, Dennis H. Cho, proposing to sell 124 common shares on 10/02/2025. Those 124 shares were acquired the prior day, 10/01/2025, by restricted stock vesting as compensation. The filing lists the broker as Fidelity Brokerage Services LLC and indicates an aggregate market value of $3,615.95 for the shares to be sold. The issuer has 60,360,925 shares outstanding per the form. The filing also discloses six prior open-market sales by Dennis H. Cho from 07/02/2025 through 09/22/2025, totaling 2,027 shares and gross proceeds of $54,048.04 across those transactions. The filer certifies no undisclosed material adverse information.
TWST Form 144 summary: This notice reports proposed and recent sales of Twist Bioscience common stock by an individual identified as Patrick Finn. The filer proposes to sell 206 shares via Fidelity Brokerage with an aggregate market value of $6,007.15 and lists the company's outstanding share count as 60,360,925. The 206 shares were acquired on 10/01/2025 through restricted stock vesting and payment is listed as compensation. The filing also discloses four reported sales in the prior three months totaling 7,470 shares for $225,564.62. The signer represents they have no undisclosed material information about the issuer.
Form 144 notice for Twist Bioscience Corp (TWST): An insider submitted a Rule 144 notice to sell 476 shares of common stock on 10/02/2025 through Fidelity Brokerage Services on the NASDAQ. The filing reports the shares were acquired by restricted stock vesting on 10/01/2025 and were paid as compensation. The filing lists 60,360,925 shares outstanding and an aggregate market value for the 476 shares of $13,880.59. The document also discloses five prior sales by the same person between 07/02/2025 and 09/22/2025 totaling 12,766 shares with gross proceeds shown for each sale. The notice contains the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a non-discretionary sale on 09/22/2025 to satisfy tax withholding for vested restricted stock units. The filing shows 233 shares disposed at $27.56 per share and the reporting person held 102,710 shares following the transaction. The sale is described as a company-mandated "sell to cover" tied to equity plan withholding, not a voluntary trade by the insider.
The Form 4 was signed on 09/24/2025 by an attorney-in-fact. No other transactions or derivative positions are reported in this filing.
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation (TWST), reported a sale of 295 shares of TWST common stock on 09/22/2025 at an average price of $27.56 per share, leaving her with 124,542 shares beneficially owned. The filing indicates the sale was a mandatory "sell to cover" transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units rather than a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact and submitted on 09/24/2025. The transaction is routine for equity compensation settlements and does not, by itself, indicate a change in officer ownership intent.
Emily M. Leproust, CEO and Director of Twist Bioscience (TWST), reported a non-discretionary sale and her current holdings. The filing shows a sale of 1,704 shares of Twist common stock on 09/22/2025 at $27.56 per share performed to satisfy tax-withholding required under the company's equity plans. After that transaction she beneficially owns 633,036 shares directly. The form also lists outstanding employee stock options with exercise prices and post-transaction holdings: $5.95 (0), $8.82 (150,879), $26.66 (266,539), $23.33 (131,290) and $67.85 (64,950). The filing notes one set of performance stock options vested and became exercisable on 12/19/2022.
Twist Bioscience (TWST) Form 144 summary: A notice was filed for a proposed sale of 1,704 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $46,962.07 and an approximate sale date of 09/22/2025. The filing states these shares were acquired on 09/22/2025 as restricted stock vesting and the payment type is listed as compensation. The issuer's number of shares outstanding is reported as 60,360,925.
The filing also discloses four prior sales by Emily M. Leproust during the past three months totaling 11,042 shares for aggregate gross proceeds of $304,506.36. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information about the issuer.
Twist Bioscience Corp (TWST) notice of proposed sale reports that 295 common shares will be offered through Fidelity Brokerage Services with an aggregate market value of $8,130.17. The filing states the shares were acquired on 09/19/2025 by restricted stock vesting and were paid as compensation on that date. The filing lists approximately 60,360,925 shares outstanding and an intended sale date of 09/22/2025 on NASDAQ.
The filer also reported four sales of common stock by Paula Green in the prior three months totaling 2,908 shares for gross proceeds of $79,786.04 (sales on 07/02/2025, 08/04/2025, 08/21/2025 and 09/08/2025). Other contact and issuer-identifying fields in the form appear blank or not provided in the content.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
